



**ABGSC Seminar -  
Autoimmunity,  
Transplantation &  
Inflammation**

**June 11, 2024**

# Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

# Global leader in antigen presenting cell (APC)-targeted immunotherapy technology



NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~\$500M<sup>1</sup>)



Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases



Broad pipeline de-risked through strong durability and survival data

- ◆ Lead asset VB10.16 in potential registrational trial in r/m cervical cancer. Expanding into additional indications with high unmet need including r/m Head and Neck



Strategic partnerships with top tier US biopharma companies<sup>2</sup>

- ◆ Personalized cancer vaccine in partnership with Genentech
- ◆ Multiprogram (oncology and infectious diseases) collaboration with Regeneron

**Genentech**  
A Member of the Roche Group

**REGENERON**



Autoimmune disease constitute a potential new therapeutic vertical in high-unmet need indications (e.g., MS, T1D)



Well-capitalized with a cash position of \$147.3m at March 31, 2024

1. Based on closing share price of NOK 16.08 on June 3, 2024 and USD/NOK exchange rate of 10.50.

2. Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab. Merck (MSD) supplies pembrolizumab

# Broad pipeline targeting early to late-stage cancer treatment

	Asset	Indication	Rights	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Catalyst
<b>Oncology</b>								
Off-the-shelf	VB10.16	HPV16+ cervical cancer	1				C-02, C-04	Finalize enrolment Pt 1 (Q4 2024)
		HPV16+ head and neck cancer	2			C-03		Dose level recommendation (H2 2024)
		HPV16+ locally advanced cervical cancer	2					C-05
	Regeneron programs	Undisclosed	3					Selection of lead candidate
	NYK011	Colorectal: pre-cancerous polyps to cancer	3					Update (H2 2024)
Individualized	VB10.NEO	Melanoma, lung, bladder, renal, head and neck cancer; locally advanced and metastatic tumors	4				N-01	
		Incurable locally advanced and metastatic tumors	4			N-02		
<b>Infectious Disease</b>								
	Regeneron programs	Undisclosed	3					
<b>Autoimmune</b>								
	Internal	Undisclosed	3					Update (H1 2024)

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.

# Strong rationale for moving into Immune Tolerance



Autoimmune disease therapy relies on broadly immunosuppressive therapies which leaves a **great unmet medical need** in a growing market




Inverse vaccines present a new promising avenue with potential for **long-lasting efficacy** and **limited side effects**



The field is gaining traction and **partnership interest from major players**, yet to see first regulatory approval

Nykode's unique approach leveraging APC-targeting technology offers a differentiated solution that could become a first- or best-in-class therapy.

# Modular design with multiple targeting and 4th modules able to ensure antigen-specific immune tolerance



**Module 1: Multiple targeting units for receptors on tolerizing APCs identified including natural ligands and other targeting molecules**


**Module 3: Auto-antigens or allergens known to elicit unwanted immune responses identified**

**Module 4: Cytokines or modulators playing key roles in mediating anti-inflammatory immune responses**



- ◆ Numerous exploratory vaccines built on above modules and evaluated experimentally
- ◆ Several patent applications covering these concepts filed

# Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs

## MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION)





# APC targeting is required for effective disease protection








# Vaccibody delivers Ag-specific suppression of EAE



# Vaccibody vaccine prevents EAE disease in an early therapeutic setting

## EAE MODEL – EARLY THERAPEUTIC DELIVERY



# Advancements highlighting the unique benefits of Nykode's APC-targeted platform for autoimmunity treatment

## Demonstrated Protection

Nykode's inverse vaccines have demonstrated protection against disease in both prophylactic and therapeutic contexts.

## Dependent on APC targeting


The effects were shown to be driven by Nykode's selective APC receptor targeting, antigen-specific and dose-dependent.

## Versatile Format


The potent tolerizing responses were reproducible with different targeting units, demonstrating the flexibility of Nykode's platform.

**Results support potency and versatility of Nykode's APC-targeted platform**

# Autoimmune indications are an attractive platform expansion category



# Nykode's successful business model validated and ready to accelerate development in autoimmune diseases



# UNLOCKING THE FUTURE OF MEDICINE

Contact:

**Agnete Fredriksen**  
**Chief Scientific Officer &**  
**Business Development**  
[abfredriksen@nykode.com](mailto:abfredriksen@nykode.com)